

# FROM RESEARCH AIMS TO ACTIONABLE MILESTONES: PLANNING, TRACKING, AND DE-RISKING YOUR PROJECT

Jaya Ghosh, PhD

Program Director | Coulter-Drexel Translational Research Partnership  
Adjunct Instructor, Pod Mentor | NSF I-Corps Hub Northeast Region  
Co-Director, Manager of Translational Boot Camps | Mizzou TechHub (NSF ART)  
Consultant Project Manager | NIH Concept to Clinic: Commercializing Innovation (C3i) Program

# Who This Talk Is For



Early translational researchers



Teams transitioning from  
R01-style planning




Scientists new to  
product-oriented execution



Applicants preparing Catalyze-like  
submissions

# Why This Matters

- ❌ Strong science alone doesn't guarantee translation/impact
- ❌ Most projects stall due to planning gaps
- ❌ Late discovery of risks is expensive
  
- ✅ Milestones help surface risks early
- ✅ Project management connects science to outcomes



# The Core Shift: Research vs. Translation

- Research focuses on discovery and learning; translation focuses on readiness and decisions
- Research tolerates ambiguity; translation reduces it
- Milestones reflect this shift in thinking

Research Aim	Translational Milestone
Knowledge-driven <i>(what do we want to learn?)</i>	Risk-focused <i>(what must be proven?)</i>
Hypothesis-focused <i>(what do we want to learn?)</i>	Decision-driven <i>(requires clear outcomes)</i>
Open-ended <i>(tolerates partial answers)</i>	Binary-ish <i>(requires clear outcomes)</i>

# What A Milestone Is/Is Not

- A predefined checkpoint tied to evidence
- Designed to support a decision (go/no-go)
  - Focused on reducing uncertainty
- Measurable and time-bound
- Used to guide next steps









YES

- A task list or workflow description
- A research aim rewritten
- “Complete experiment X”
- Vague statements of progress
- Success by effort alone




NO

# What Milestones Do

-  Clarify whether progress is sufficient
-  Enable prioritization and sequencing of work
-  Reduce subjective decision-making by addressing key translational risks
-  Support course correction
-  Signal readiness to external stakeholders
-  Support responsible use of resources

# What Good Milestones Measure



# Diagnostic Technology Example

## A BLOOD BASED DIAGNOSTIC ASSAY TO DETECT EARLY PULMONARY VASCULAR REMODELING IN PATIENTS AT RISK FOR PULMONARY HYPERTENSION (PH)

<p><b>Hypothesis-Driven Research Aim:</b>  <i>Circulating biomarker X correlates with early pulmonary vascular remodeling in animal models and human samples</i></p>	<p><b>Translational Objective:</b>  <i>Determine whether biomarker X can be developed into a viable early-stage diagnostic for PH</i></p>
<p><b>Characteristics</b></p> <ul style="list-style-type: none"> <li>• Focused on <b>biological insight</b></li> <li>• Open-ended scope</li> <li>• Success defined by <b>statistical significance</b></li> <li>• Generates new questions rather than decisions</li> </ul>	<p><b>Milestone 1: Analytical &amp; Clinical Feasibility</b></p> <p><b>Deliverables (Defined):</b></p> <ul style="list-style-type: none"> <li>• Develop and <b>lock a prototype assay</b></li> <li>• Demonstrate: Sensitivity <math>\geq 85\%</math>, Specificity <math>\geq 80\%</math>, Coefficient of variation (CV) <math>\leq 15\%</math></li> <li>• Evaluate performance in: <math>\geq 50</math> <b>archived patient samples</b>, Pre-defined intended-use population</li> <li>• <b>Timeline:</b> 6 months</li> </ul>
<p><b>Typical Outcomes</b></p> <ul style="list-style-type: none"> <li>• Publications</li> <li>• Follow-on hypotheses</li> <li>• Additional grant proposals</li> </ul>	<p><b>Go/No-Go Decision</b></p> <ul style="list-style-type: none"> <li>• <b>GO if:</b> All performance thresholds are met, Reproducibility is demonstrated, Preliminary differentiation from standard of care is plausible</li> <li>• <b>NO-GO/PIVOT if:</b> Performance falls below thresholds, Variability is too high, Clinical utility remains unclear</li> </ul>

# Side-by-Side Comparison

Dimension	Hypothesis-Driven Aim	Translational Milestone
Primary Question	“Is this interesting?”	“Is this viable?”
Outcome	Knowledge	Decision
Metrics	p-values	Sensitivity, specificity, CV
Timeline	Open-ended	Fixed
Success	Interpretation-based	Threshold-based
Consequence	More research	Go/No-Go


Strong translational proposals don't just propose experiments.  
They propose *decisions that reduce risk*.

# Why Milestones Enable Project Management

- Make ambiguity explicit by surfacing assumptions
- Tie progress to evidence, not activity
- Enable early identification of technical, regulatory, and adoption risks
- Allow progress to be tracked objectively over time
- Create structured go/no-go decision points
- Allow replanning when assumptions fail

# Who Is A Project Manager? What Do They Do?

- Not just an administrator/scheduler
- Often a scientist/founder
- Accountable for alignment across contributors, not final decisions
- Brings an independent, risk-focused lens
- Helps keep momentum without losing rigor



# External Interfaces PMs May Track

- Regulatory pathways (e.g., FDA expectations)
- IP and TTO/innovation ecosystem Integration
- Reimbursement considerations
- Adoption logic
- Manufacturing/scalability considerations
- Stakeholder expectations and timelines

# How A PM May Work With A Team



Works with the PI and team to define and track clear, testable milestones



Helps identify and track key risks across science, regulatory, IP, and adoption pathways



Keeps the project aligned with funder expectations and external requirements



Facilitates evidence-based decisions at milestone checkpoints (advance, pivot, pause)



Acts as a neutral, independent lens – asking hard questions and identifying issues early

# Common Applicant Pitfalls



- Milestones that describe effort, not evidence
- Success criteria that are vague
- Treating milestones as formalities
- Ignoring non-technical and product-development risks
- Not anticipating likely failures or troubleshooting paths
- Mistaking familiarity for evidence

# Better Milestone Design Questions



- What assumption does this test?
- What risk does this reduce?
- What does success look like, concretely?
- What happens if it fails?
- Who cares about this result?

# Setting Realistic Milestones & Tracking Progress



Balance ambition with feasibility



Define success criteria upfront



Track progress against evidence, not effort



Use regular check-ins to assess status



Adjust plans before issues compound

# Anticipating Challenges, Using Go/No-Go Decisions

Be prepared to identify and address research translation risks early:

- Watching for warning signs (missed criteria, shifting goals)
- Using milestones as formal decision points
- Pivoting when evidence suggests a better path
- Stopping early can be a success

# Example: Weak vs. Strong Milestone (Therapeutic)

<b>Weak Milestone:</b> <i>Demonstrate efficacy of the therapeutic in a preclinical model</i>	<b>Stronger Milestone:</b> <i>Demonstrate that the therapeutic achieves a <math>\geq 25\%</math> improvement in cardiac function compared to standard of care in a validated large animal heart failure model, with no dose-limiting toxicity observed over 28 days</i>
<b>Why this is weak</b> <ul style="list-style-type: none"><li>• Vague success criteria (what level of efficacy?)</li><li>• No indication of model relevance to human disease</li><li>• Doesn't enable a clear decision</li><li>• Could be interpreted as partial success</li></ul>	<b>Why this is strong</b> <ul style="list-style-type: none"><li>• Defines what success looks like quantitatively</li><li>• Uses a clinically relevant model</li><li>• Addresses both efficacy and safety risk</li><li>• Enables a clear go/no-go decision for further development</li></ul>

# What Reviewers Often Want To See

- ✓ Clear linkage between milestones and key product development risks
- ✓ Objective, measurable success criteria
- ✓ A realistic plan that enables a go/no-go decision
- ✓ Awareness of regulatory, IP, reimbursement, market, and adoption context
- ✓ Willingness to make evidence-based decisions

# R01 Thinking vs. Catalyze Thinking

- Knowledge generation → Risk mitigation
- Long-term exploration → Staged decisions
- PI/Lab-centric work → Stakeholder-based accountability
- Flexibility → Structured progress
- Curiosity → Readiness

# If You're Considering A PM Role



**You don't need "PM" in your title – many start as scientists wearing multiple hats**



**Strong PMs are curious, organized, and comfortable asking hard questions**



**Requires thinking beyond the bench: regulatory, IP, reimbursement, adoption**







**Success means enabling decisions, not owning all the answers**



**Learn to separate what's interesting from what's necessary to move forward**

# Leveraging Catalyze Support

## Project Management Resources

Project Management	Medical Product Development	Regulatory Affairs	Commercialization
 <p>Milestones</p>	 <p>Building Your Project Team</p>	 <p>Nuts and Bolts</p>	 <p>Resources</p>
<p>A practical guide to designing clear, decision-driven milestones that help Catalyze teams reduce risk, demonstrate progress, and move translational projects forward.</p>	<p>An overview of the key roles and skill sets needed for translational research teams, and guidance on building a well-balanced project team that can successfully move a technology from research toward real-world impact.</p>	<p>A practical overview of the core project management fundamentals – covering planning, tracking progress, managing risk, and keeping translational research projects organized and moving forward effectively.</p>	<p>A curated collection of project management templates, tools, and guidance to help Catalyze teams plan, track, and manage translational research projects more effectively.</p>

# Key Takeaways

1

Milestones  
drive  
decisions –  
not just  
progress

2

Realistic  
planning  
sustains  
momentum

3

Project  
management  
reduces  
surprise and  
risk

4

Evidence  
should guide  
pivots and  
stops

5

Strong  
execution  
accelerates  
impact

# It Takes A Village To Raise A Business

Source: LinkedIn



Jaya Ghosh, PhD

 [jg3948@drexel.edu](mailto:jg3948@drexel.edu)

 <https://www.linkedin.com/in/ghoshjaya/>

IT TAKES A VILLAGE TO BUILD A BUSINESS — AND PROJECT MANAGEMENT IS HOW THAT VILLAGE WORKS TOGETHER TO DELIVER RESULTS!